# EDGAR Filing Document

**Accession Number:** 0001912966
**File Stem:** 0001213900-25-086109
**Filing Date:** 2025-9
**Character Count:** 4687
**Document Hash:** 8743280c0fdd890544b3e427b6994750
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-086109.hdr.sgml**: 20250909

**ACCESSION NUMBER**: 0001213900-25-086109

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250909

**DATE AS OF CHANGE**: 20250909

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REGENTIS BIOMATERIALS LTD.
- **CENTRAL INDEX KEY:** 0001912966
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42834
- **FILM NUMBER:** 251303004

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HA'ILAN STREET, NORTHERN INDUSTRIAL
- **STREET 2:** ZONE, P.O. BOX 260
- **CITY:** OR AKIVA
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 30600

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HA'ILAN STREET, NORTHERN INDUSTRIAL
- **STREET 2:** ZONE, P.O. BOX 260
- **CITY:** OR AKIVA
- **PROVINCE COUNTRY:** L3

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES** 

**PURSUANT TO SECTION 12(b) OR (g) OF** 

**THE SECURITIES EXCHANGE ACT OF l934** 

**REGENTIS BIOMATERIALS LTD.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **State of Israel** | **Not Applicable** |
| **(State of incorporation <br> or organization)** | **(I.R.S. Employer <br> Identification No.)** |

---

---

| | |
|:---|:---|
| **60 Medinat Hayehudim**<br> **Herzliya, Israel**<br> **Tel: +972 (9) 960-1917** | **4676652** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Securities to be registered pursuant to Section 12(b) of the Act:** 

---

| | |
|:---|:---|
| **Title of each class**<br> **to be so registered** | **Name of each exchange on which**<br> **each class is to be registered** |
| **Ordinary Shares, no par value** | **NYSE American, LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

**Securities Act registration statement file number to which this form relates:** 

**333-285692**

**Securities to be registered pursuant to Section 12(g) of the Act:** 

**None** 

**(Title of Class)**

**Item 1. Description of Registrant's Securities to be Registered.** 

Regentis Biomaterials Ltd. (the "***Registrant***") hereby incorporates by reference the description of its ordinary shares, no par value, to be registered hereunder, contained under the heading "Description of Share Capital" in the Registrant's Registration Statement on [Form F-1](http://www.sec.gov/Archives/edgar/data/1912966/000121390025022350/ea0233222-f1_regentisbio.htm) (File No. 333-285692), originally filed with the Securities and Exchange Commission (the "***Commission***") under the Securities Act of 1933, as amended (the "***Securities Act***") on March 11, 2025, as subsequently amended (the "***Registration Statement***"), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, which information shall be deemed to be incorporated herein by reference.

**Item 2. Exhibits.** 

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on NYSE American, LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the <u>Securities Exchange Act of 1934</u>, as amended.

**SIGNATURE** 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Regentis Biomaterials Ltd.** | **Regentis Biomaterials Ltd.** |
| By: | */s/ Dr. Eli Hazum* |
| Name: | Dr. Eli Hazum |
| Title: | Chief Executive Officer |

---

Dated: September 9, 2025